Feb 28 Anacor Pharmaceuticals' said its
experimental drug to treat a fungal infection of the nail
achieved a cure rate of 9.1 percent in the second of two
Only 1.5 percent of the patients on the placebo achieved the
An earlier late-stage study had achieved a complete cure
rate of 6.5 percent.
Tavaborole was safe and well-tolerated, the company said,
adding that there were no serious adverse events related to the
Anacor said it was on track to file a marketing application
with the U.S. health regulator by the middle of the year.
Anacor's shares had fallen in January to their lowest in 18
months after it reported data from the first trial as the
numbers were seen to be trailing those of a competing drug from
Valeant Pharmaceuticals International Inc.
Anacor shares closed at $3.49 on Thursday on the Nasdaq.